National Institute on Aging (NIA)
This sponsor has funded 3 studies across 2 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 44899 | Finalised | Comparative Effectiveness and Safety of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in Older Adults with... | Yes | No |
| 107225 | Finalised | Effect of Incretin Analogues and Dipeptidyl-peptidase-IV inhibitors on the risk of thyroid cancer | Yes | No |
| 108001 | Ongoing | Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: Impact of Study Design Differences on Comparative Safety Results | Yes | No |
PAS by Risk Management Plan (RMP) requirement
National Institute on Aging (NIA)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
National Institute on Aging (NIA)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
National Institute on Aging (NIA)
2 Study countries specified are the following:
- Switzerland
- United States